Press Releases
CAESAREA, Israel –(BUSINESS WIRE)– Mazor Robotics Ltd. (NASDAQCM:MZOR; TASE:MZOR), the developer of Renaissance®, an innovative surgical guidance system and its complementary products, announced today that it has received an order for a Renaissance system from Transmedic Pte Ltd., its distribution partner in Southeast Asia. The purchase of the system by Transmedic is another step in Mazors’ footprint expansion and momentum throughout the Asia Pacific region.
This order demonstrates the continued market acceptance of Mazor Robotics’ Renaissance system in the Asia Pacific market with systems already in clinical use in Taiwan, Vietnam and India. Mazor is targeting the Asia Pacific region as a prime market following the U.S. market, and established distribution agreements in China, Japan and Australia.
“Asia Pacific represents a significant growth opportunity for Mazor,” commented Ori Hadomi, Chief Executive Officer. “We are very pleased with our recent success in the Asia Pacific market, both at the clinical utilization level as well as at the expansion of our install base. I believe these developments continue to validate our business and sales model in the international markets, particularly in Asia Pacific.”
Transmedic Pte Ltd. was founded in 1980 and is headquartered in Singapore. Transmedic represents a wide range of medical device manufacturers and its reputation has been built upon its success of collaborating with surgical robotic companies in the Asia Pacific markets.
About Mazor
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expectations for growth in system sales and recurring revenue, the Company’s expected sales in 2016, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.
U.S. Contacts: EVC Group
Michael Polyviou/Doug Sherk – Investors
mpolyviou@evcgroup.com; dsherk@evcgroup.com
212.850.6020; 646-445-4800
David Schemelia – Media
646.201.5431
Latest Tweet
Mazor #CoreTechnology can help you produce consistent results that lead to improved clinical outcomes. Get more inf… https://t.co/LJDbcI17O1